Clinical development financing · Biotech
Connecta Therapeutics raises €3.1m for its Fragile X clinical programme
Clave Capital led the financing to accelerate the ongoing Phase IIa trial of CTH120, with existing investors participating.
Support for the ongoing Phase IIa study
Connecta’s €3.1 million financing will accelerate the ongoing Phase IIa trial of CTH120 for Fragile X syndrome. New investor Clave Capital led through its Innvierte Science Tech Clave Innohealth fund, with Inveready, CDTI Innvierte and Prous Institute for Biomedical Research participating.
The financing adds a new investor alongside the existing backers as the company develops its lead neuroplasticity-modulation programme. CTH120 is being evaluated as a potential disease-modifying treatment.
Use of funds
Expand operations and clinical development efforts.
Funding history
Clinical development financing · This round€3.1M